Posted on 23/02/2010 in Pharmaceutical Company Product News Novartis has had its application for approval of its meningococcal disease vaccine Menveo approved by the Food and Drug Administration (FDA).
The regulator ratified the compound for use as a treatment for adolescents and adults based on positive findings from a phase III trial, during which the drug demonstrated its efficacy in encouraging an immune response to the potentially fatal illness.
This approval represents the culmination of a decade-long development process for Novartis, which described the news as an "important milestone" in the treatment of the disease.
Andrin Oswald, division head of Novartis Vaccines and Diagnostics, stated that the production of treatments for this condition is particularly vital due its potential effect on previously healthy adolescents.
He added that the approval of Menveo is indicative of the company's commitment to eradicating the illness across the world.
Earlier this month, the company was granted a priority FDA review of its new leukaemia drug Tasigna following promising results from a clinical trial.Other news stories from 23/02/2010
Read more in the Zenopa News Archive
How this news is generated
|
